Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis - European Medical Journal

Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Oncology

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments. At 24 weeks of treatment, 19.1% of patients on the pacritinib arm experienced spleen shrinkage, compared to only 4.7% of patients on the BAT arm.

Presented by Ruben A. Mesa, MD, Mayo Clinic Cancer Center, Scottsdale, AZ, at ASCO 2015.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>